Option chain shows key data for Hansoh Pharmaceutical Gr's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Hansoh Pharmaceutical Gr.

Hansoh Pharmaceutical Gr (OTC:HNSPF) Stock, Option Chain

Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.

Headquarters_Rahway-Site-Entrance_HI

Technicals

Trading Ideas

HNSPF

PSNL

Shares of Merck &amp; Co (MRK) continue to trend lower. If they reach the $95.00 level, there is a good chance they find support and reverse.

Stock Of The Day: Where Does The Merck Downtrend End?

Asia

News

Penny Stocks

Markets

General

AAGIY

BABA

CICHY

MPNGY

PNGAY

SBMFF

TCEHY

TSLA

WXXWY

XPEV

NIKE

Hong Kong stocks rallied Friday as the week closed out higher for consumer stocks and EV makers which investors hope will be the beneficiary of a forthcoming government stimulus.  

The Hang Seng Index ended the day 2.1% higher at 17,398.73 while China’s CSI 300 Index rose 1.4% to 3,562.39.

Strong Consumer Turnout Drives Hong Kong Stocks Higher Friday As China&#39;s Former Premier Li Keqiang Dies At 68

HANSOH PHARMACEUTICAL GP by Hansoh Pharmaceutical Group Co Ltd.

Hansoh Pharmaceutical Group Co Ltd

Hancock Whitney Acquires Sabal Trust Company, Terms Not Disclosed

Barclays analyst Benjamin Theurer maintains Archer-Daniels Midland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) with a Underweight and lowers the price target from $56 to $50.

Price Target

Analyst Ratings

Barclays Maintains Underweight on Archer-Daniels Midland, Lowers Price Target to $50

XTI Aerospace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) ("XTI"), a pioneer in advanced aircraft design, announces its access to&nbsp;computing resources on the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4344566-1&amp;h=3097513963&amp;u=https%3A%2F%2Fwww.olcf.ornl.gov%2Ffrontier%2F&amp;a=Frontier">Frontier</a> supercomputer&nbsp;at Oak Ridge National Laboratory's (ORNL) Leadership Computing Facility. Frontier, the world's first exascale supercomputer and currently ranked as the second most powerful commercially available computing system in the world,&nbsp;will provide XTI with unmatched computational capabilities&nbsp;to accelerate development of the&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4344566-1&amp;h=391327699&amp;u=https%3A%2F%2Fxtiaerospace.com%2Ftrifan-600-vlca%2F&amp;a=TriFan+600">TriFan 600</a> aircraft, the Company's vertical takeoff and landing (VTOL) aircraft that combines the operational flexibility of helicopters with the speed and range of fixed-wing airplanes.
Frontier, managed by the Department of Energy's Oak Ridge National Laboratory, is capable of executing over a quintillion calculations per second. XTI's access&nbsp;to this transformative technology&nbsp;underscores the significance of the TriFan&nbsp;600 project and its potential to contribute to the evolution of sustainable, next-generation aviation technologies.
Specifically, Frontier's advanced computational power will allow XTI to perform highly detailed computational fluid dynamics (CFD) simulations with precision. These simulations will optimize the aerodynamic performance of the TriFan 600, further refining its design to meet rigorous engineering and performance standards. Leveraging Frontier's capabilities, XTI will focus on refining critical design features, such as the fan duct and the transition between vertical and horizontal flight modes, ensuring the aircraft delivers peak performance and efficiency.

XTIA

XTI Accesses Frontier Supercomputer To Enhance TriFan 600 VTOL Aircraft Development; Focus On Aerodynamic Performance Optimization Using Exascale Capabilities

Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) may be riding the Edge AI wave, but it's also facing a riptide of headwinds. JPMorgan analyst Samik Chatterjee sees currency woes, China struggles, and lukewarm AI adoption as hurdles for the tech giant's upcoming earnings—and warns that <a href="https://www.benzinga.com/quote/AAPL/guidance">guidance could disappoint investors</a>.
<h2 class="wp-block-heading">China's Chilling Effect</h2>
Apple's grip on China is loosening, and Chatterjee isn't mincing words. "Share loss in China to likely continue with the company already past its product cycle peak and with the consumer subsidies from the local administration to enable smartphone replacement for low to mid-tier phones, which excludes high-end smartphones." 
With Beijing's push to boost domestic brands, Apple is losing its competitive edge in a critical growth market.
Read Also: <a href="https://www.benzinga.com/markets/equities/25/01/43087992/apple-gets-rare-downgrade-from-jefferies-analyst-warns-on-slowing-revenue-growth-missed-forecasts-and-falling-iphone-demand">Apple Gets Rare Downgrade From Jefferies, Analyst Warns On Slowing Revenue Growth, Missed Forecasts, And Falling iPhone Demand</a>
<h2 class="wp-block-heading">AI: The Game-Changer That Isn't (Yet)</h2>
Despite Apple's push into Edge AI, Chatterjee sees a slow build rather than a sudden spike in demand. "Limited traction yet for the AI features rolled out increasing the likelihood of flattish unit sales as we go through the upcoming quarters, although downside to unit sales remain limited given trough replacement rates already." 
Simply put, consumers aren't rushing to upgrade just for AI, leaving iPhone sales stuck in neutral.
<h2 class="wp-block-heading">Strong Dollar, Weak Outlook?</h2>
The dollar's strength is another thorn in Apple's side, making overseas sales less profitable. "Stronger USD to increase headwinds for Apple to navigate in the coming quarters, given limited appetite to adjust pricing outside of new product launches." 
This could mean Apple absorbs the hit rather than passing costs to customers, squeezing margins further.
<h2 class="wp-block-heading">Apple Earnings Outlook: A Tough Climb</h2>
Chatterjee expects Apple's first quarter earnings to come in at $2.33 per share on $123 billion in revenue—just shy of consensus estimates. But it's the guidance that could really spook investors. Revenue for the quarter is expected to land at $94.8 billion, trailing consensus expectations, as China's smartphone subsidies and AI's slow ramp-up weigh on demand.
Still, Chatterjee isn't ditching Apple altogether. He maintains an Overweight rating, banking on Apple's premium valuation holding up thanks to its ecosystem and AI ambitions. 
However, he trims his December 2025 price target from $265 to $260, warning that earnings revisions from a softer guide could pressure shares in the near term.
Apple may have long-term AI potential, but for now, it's a battle of innovation versus macro headwinds. And according to Chatterjee, the next earnings report could be a reality check for investors.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/asia/25/01/43088007/nvidia-apple-supplier-tsmc-halts-production-as-6-4-magnitude-earthquake-strikes-taiwan">Nvidia, Apple-Supplier TSMC Halts Production As 6.4 Magnitude Earthquake Strikes Taiwan</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

Tech

AAPL

Apple's AI Advances Can't Offset Chinese Market Slowdown, Says Analyst

Barclays analyst Benjamin Theurer maintains Ambev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEV#NYSE">ABEV</a>) with a Equal-Weight and lowers the price target from $2.5 to $2.

ABEV

Barclays Maintains Equal-Weight on Ambev, Lowers Price Target to $2

SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis&#xAE;) with the potential to improve trabectedin's therapeutic window in soft-tissue sarcoma patients
Combined mechanisms have the potential to enhance progression-free survival (PFS) in some of the largest cohorts of patients with soft-tissue sarcoma
Topline safety data of the combination of SON-1010 with trabectedin is expected in H2 calendar year 2025
Sonnet management discusses what this expansion means in a Virtual Investor "What This Means" segment; <a href="https://www.globenewswire.com/Tracker?data=nOlP7iC56ckndPUZ0KGseRUZe097r20n2xnUzb8MTGHgD_HoQdCt66MvD0pUnZiOBVouh2x2H0abDjAs5G5S-bN262mZMXBfeUqWzgyy85MgfxRhjJpqZrE9egvaXGy8">Access here</a> &nbsp;
PRINCETON, NJ, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today an expansion of its Phase 1 SB101 clinical study of SON-1010 (IL12-FHAB) in adult patients with advanced solid tumors to add a new cohort to evaluate the effect of SON-1010 in combination with trabectedin (Yondelis&#xAE;), following the <a href="https://www.globenewswire.com/Tracker?data=J602bu1osG4rjFxVMgjgjaooaMVaw8t_NZONgF691oyejdeNL6wHCOcdFz97qc0T2V10KkciXWdv4vLeIXWFjcBPeFYxWJltOWSahT1HTcHDFlLipqzmnAlAKWfC3xHtA0uUNX05jQ2v9PJThyRfA1QzHE8nHr-i2WkJfvoa7mlUAp61IfPAjiyKbbI9tah43Kd46oJA37d4o-I8_cHmdswMjRC1s9Trjv88CRTli4qs-d0Tm7yRFHf4cHRBqP0k">successful completion of monotherapy dose escalation</a>. This expansion will explore the immune-oncology impact of SON-1010 at the maximum tolerated (MTD) dose of 1200 ng/kg in combination with trabectedin, which is an approved chemotherapeutic drug for certain advanced soft-tissue sarcomas (STS). Patients with STS could potentially benefit from an enhanced local immune response in the tumor microenvironment (TME). Enrollment in this cohort is underway and is expected to be completed in H1 calendar year 2025. Topline safety data of the combination with trabectedin is expected in H2 calendar year 2025; no new safety concerns have been reported to date. Additionally, the Company announced the release of a "What This Means" segment to discuss the expansion of the Phase 1 clinical study which is now available <a href="https://www.globenewswire.com/Tracker?data=_TlK7xwSKTa_TAoTgrAzhNOrT5fFiakN0E5Ml5eMkWwCi1P30-61e9EGxoa98WZlywjPBVKDYBUDtA-RgPN6aInB7EBDNIlb5zIqowG5OG_9z5C0D8ptnquYiEYgoY8R">here</a>.
"The Sarcoma Oncology Center is pleased to have been able to enroll most of the patients in Sonnet's Phase1 SB101 study to date, with the majority of the patients having STS," commented Dr. Sant Chawla, Principal Investigator at the Sarcoma Oncology Center in Santa Monica, California. "Additionally, as we have contributed to the development of trabectedin over the years, we were excited to see its approval in early 2024 as a monotherapy in the second-line treatment for two of the most common types of sarcoma — liposarcoma and leiomyosarcoma. While the trabectedin approval was based on several clinical trials in sarcoma, we believe a large unmet need remains for the treatment of STS. We believe that combining trabectedin with SON-1010 has the potential for a natural synergistic effect of the two mechanisms of action."
The Company expects to enroll up to 18 patients with unresectable, metastatic liposarcoma or leiomyosarcoma in this open-label, single-arm expansion cohort. The patients will be treated with SON-1010 in combination with the standard 21-day trabectedin cycles, alternating the dosing of the two drugs. This number of subjects may be needed to see a statistical benefit in the response using the standard RECIST paradigm. The primary outcome measures for the Phase 1 SB101 trial are the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of SON-1010 and to establish the MTD, which has been set at 1200 ng/kg. The Company believes the results of this expansion cohort could position SON-1010 for a larger Phase 2 study that could establish the combination of SON-1010 and trabectedin as a new and potentially improved treatment for STS.
"The ability to assess earlier-stage patients is an exciting opportunity to evaluate the potential for SON-1010 to turn ‘cold' tumors ‘hot'," said Richard Kenney, M.D., Sonnet's Chief Medical Officer. "Most Phase 1 studies in the oncology space are done in patients with advanced disease, whose immune systems may not respond optimally after multiple types of chemotherapy. Trabectedin's approval as a single agent second-line therapy in STS provides access to patients at an earlier stage with an underlying immune response that may be more robust."
"The Sonnet team has been studying the efficacy and safety of SON-1010 as a single agent, which has thus far suggested clinical benefit when administered as a monotherapy in patients with advanced solid tumors," said Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer. "Further, we believe this synergy could improve the response in a serious type of cancer at an earlier stage of disease, which could open up another potential opportunity for partnering."
SON-1010 is the Company's proprietary version of recombinant human interleukin-12 (rhIL-12), configured using genetic fusion to Sonnet's Fully Human Albumin Binding (FHAB&#xAE;) platform, which extends the half-life and bioactivity of the IL-12 component due to binding native albumin in the serum. Albumin naturally targets the TME by strong binding to gp60 and Secreted Protein Acidic and Rich in Cysteine (SPARC). The majority of patients enrolled to date in the Phase 1 SB101 trial have STS, which has a known potential for an enhanced response to immunotherapy.

Biotech

SONN

Sonnet Expands Phase 1 SB101 Study Of SON-1010, Combining With Trabectedin In Advanced Soft-Tissue Sarcoma; Enrollment Of 18 Patients Expected By H1 2025; Topline Safety Data Due H2 2025; Monotherapy Suggested Clinical Benefit; Potential Phase 2 Study Envisioned

NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRXS#NYSE">NRXS</a>), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), with Molina Healthcare. Molina, with over 40 years in operation, has approximately 5.1 million members across 13 states.
NeurAxis' PENFS technology, IB-Stim, is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. IB-Stim is a non-surgical device that sends gentle electrical impulses into cranial nerve bundles in the ear. There are currently no FDA-approved drug therapies for children with abdominal pain-related disorders of the gut-brain interaction. Off label pharmacologic treatments can often have serious side effects, and most lack scientific evidence of efficacy.

NRXS

NeurAxis Announces Molina Healthcare Coverage For PENFS Therapy IB-Stim, FDA-Cleared For Treating Abdominal Pain In IBS Adolescents

Donald Trump wasted no time in his return to the White House, signing a flurry of executive orders, and, most notably, declaring <a href="https://www.benzinga.com/government/regulations/25/01/43086509/trump-unleashes-executive-orders-on-border-security-oil-drilling-domestic-manufacturing-in-first-acts-as-president">a national energy emergency. </a>
During his inauguration speech on Monday, he reaffirmed his commitment to fossil fuels, pledging to &#8220;drill, baby, drill&#8221; and revoke the electric vehicle mandate. 
&#8220;The inflation crisis was caused by massive overspending and escalating energy prices. And that is why today I will also declare a national energy emergency. We will drill, baby, drill,&#8221; Trump said. 
Trump also announced his intent to withdraw the U.S. from the Paris Climate Accord, calling wind turbines "ugly" and reiterating his policy against renewable energy expansion. His focus is clear: expand drilling, restore the Strategic Petroleum Reserve and flood global markets with U.S. oil and gas.
Oil markets are already reacting, but will this push for American energy dominance send crude prices soaring or lead to an oversupply crisis?
<h3 class="wp-block-heading">What Happens To Oil Prices?</h3>
The immediate impact of Trump's pro-drilling stance on oil markets has been strong, with traders already reassessing their outlooks on crude prices. 
The U.S. benchmark West Texas Intermediate crude – as tracked by the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) – tumbled by 2.6% during morning trading on Tuesday, heading for a third straight session of losses. 
"Mr. Trump's full-throated yell for U.S. producers to: ‘Drill, baby, drill!' is not new. And it's perfectly logical that prices should fall at the prospect of increased supply. But producers are highly price-sensitive, and there comes a time/price where it's uneconomical to raise production," commented David Morrison, senior market analyst at Trade Nation.
&#8220;Day 1 executive orders in these areas are expected to be followed by further action in the coming days and weeks, with Trump set to test the limits of presidential authority to pursue an agenda that aims to unravel Biden's energy and climate policies,&#8221; wrote Energy Intelligence in a note Tuesday. 
David Goldman, head of trading at Novion said Trump's policy shift "is unlikely to have any significant impact in the short term but may have bearish repercussions in the long term."
Goldman highlighted that a sharp increase in U.S. production, particularly if global demand slows due to the ongoing transition to renewable energy, could weigh on prices. "Increased production without sufficient export infrastructure risks bottlenecks, while protectionist trade measures could stifle international cooperation and reduce market efficiency."
<h3 class="wp-block-heading">Energy Stocks See A Small Lift</h3>
Oil and gas stocks saw modest gains in premarket trading Tuesday as investors weighed the potential for increased drilling activity. 
The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>), which tracks major oil companies, was up 0.1% during premarket trading, while the SPDR S&amp;P Oil &amp; Gas Exploration &amp; Production ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOP#NYSE">XOP</a>) saw similar gains.
Among individual stocks:
<ul>
<li>Halliburton Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) rose 1.67% </li>
<li>Texas Pacific Land Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPL#NYSE">TPL</a>) gained 1.04%</li>
<li>Schlumberger Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) climbed 1.04% to $44.03</li>
<li>Kinder Morgan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) increased 0.96% to $30.60</li>
<li>Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) moved 0.90% higher to $46.96</li>
</ul>
Smaller energy players saw sharper moves, with Gulfport Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPOR#NYSE">GPOR</a>) surging 9.13% to $213.25 and Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) jumping 5.20% to $25.77.
Read now: 
<ul>
<li><a href="https://www.benzinga.com/markets/futures/25/01/43093520/us-stocks-set-to-open-on-a-positive-note-as-trumps-second-white-house-term-kicks-off-tesla-apple-netflix-among-stocks-in-focus">US Stocks Set To Open On A Positive Note As Trump&#8217;s Second White House Term Kicks Off: Tesla, Apple, Netflix Among Stocks In Focus</a></li>
</ul>
Photo Shutterstock

Government

Regulations

Sector ETFs

Commodities

Econ #s

Economics

ETFs

GPOR

Trump's 'Drill, Baby, Drill' Era Begins: Oil Prices Tumble, US Energy Stocks Edge Up

Strategic collaboration formed to raise awareness that all people with diabetes on blood glucose-lowering medications should have glucagon, preferable a ready-to-use formulation
CHICAGO and ARLINGTON, Va., Jan. 21, 2025 /PRNewswire/ -- The American Diabetes Association&#xAE; (ADA) and Xeris Pharmaceuticals&#xAE; (Xeris BioPharma Holdings, Inc.), a national supporter of the ADA, are pleased to announce a multi-year strategic partnership to reinforce the importance of prescribing glucagon, preferably ready-to-use, for all individuals with diabetes who are treated with insulin and/or insulin secretagogues or those at high risk of hypoglycemia (low blood glucose, also called low blood sugar), in line with the ADA's recently updated Standards of Care in Diabetes—2025 (Standards of Care).1

XERS

American Diabetes Association And Xeris BioPharma Holdings Announce Multi-Year Partnership To Promote Ready-To-Use Glucagon For Individuals With Diabetes On Blood Glucose-Lowering Medications, Following Updated 2025 Standards Of Care

Contracts

Curtiss-Wright Receives $27M Contract To Provide Aircraft Handling Systems And Support For US Navy Constellation Class Frigates

JBLU

Jetblue Becomes First Airline To Accept Venmo For Flight Booking

JP Morgan analyst Alexander Hess maintains MSCI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) with a Overweight and raises the price target from $680 to $700.

MSCI

JP Morgan Maintains Overweight on MSCI, Raises Price Target to $700

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today that it has achieved 25% enrollment in the initial randomized portion of its Phase 2 Clinical Trial of Ropidoxuridine for the treatment of patients with glioblastoma.
The Phase 2 trial design is to initially randomize 40 patients into two different dose levels, with 20 patients receiving 1,200 mg/day and 20 patients receiving 960 mg/day, to determine an optimal dose for use in glioblastoma patients. Once the optimal dose is identified, 14 additional patients will be enrolled at the optimal dose to reach statistical significance with the end-point demonstrating survival as compared to historical controls. The Phase 2 clinical trial is being conducted on patients presenting with the most aggressive form of brain tumors– IDH wild-type, methylation negative glioblastoma. This cohort of patients currently only have radiation as the standard of care, with less than half of the patients surviving beyond 12 months after diagnosis.
Ropidoxuridine (IPdR) is Shuttle Pharma's lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure. Shuttle Pharma previously received Orphan Drug Designation from the FDA, providing Shuttle Pharma with potential marketing exclusivity upon obtaining FDA approval for treatment of this disease.

SHPH

Shuttle Pharma Announces 25% Enrollment In Phase 2 Trial For Ropidoxuridine In Treating Aggressive Glioblastoma; Trial Targets Optimal Dosing Among 40 Patients; Conducted At Multiple U.S. Medical Centers; Aims To Prove Survival Endpoint

Cognizant Technology Solutions Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>) shares are trading higher premarket on Tuesday. The company has inked a partnership with CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n43088824/cognizant-and-crowdstrike-partner-to-drive-enterprise-cybersecurity-transformation" rel="noreferrer noopener">to enhance enterprise security</a>.
The collaboration will leverage CrowdStrike&#8217;s AI-powered Falcon cybersecurity platform to help organizations streamline security operations, consolidate legacy products, simplify cybersecurity management, and improve security posture using Falcon Next-Gen SIEM and Falcon Cloud Security.
Ravi Kumar S, CEO, Cognizant said, &#8220;As the enterprise digital landscape evolves, it is crucial to leverage AI for cybersecurity and cloud-native security technologies to help stay ahead of threats and ensure the resilience of our clients&#8217; infrastructure.&#8221;
George Kurtz, CEO and founder, CrowdStrike added, &#8220;CrowdStrike&#8217;s AI-native Falcon platform with Cognizant&#8217;s extensive expertise in technology transformation offers customers best-in-class protection, performance, and efficiency.&#8221;
Last week, Cognizant introduced its Neuro AI Multi-Agent Accelerator and Multi-Agent Service Suite, which is expected to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n43020076/cognizant-leads-enterprises-into-next-generation-of-ai-adoption-with-neuro-ai-multi-agent-accelera" rel="noreferrer noopener">accelerate AI agent adoption</a>.
The company is expected to release fourth-quarter <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">results on February 5, 2025</a>.
Investors can gain exposure to the stock via Northern Lights Fund Trust IV Monarch Dividend Plus Index ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MDPL#BATS">MDPL</a>) and ETF Opportunities Trust Formidable Fortress ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KONG#NYSE">KONG</a>).
Price Action: CTSH shares are up 2.81% at $80.00 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43091062" target="_blank" rel="noreferrer noopener">Amazon&#8217;s Zoox Eyes Joining Leagues Of Waymo In 2025, To Offer Rides To Public &#8216;Quite Soon</a>&#8216;</li>
</ul>
Photo via Shutterstock.

Equities

Large Cap

Movers

CRWD

CTSH

KONG

MDPL

Cognizant Teams with CrowdStrike To Fortify Enterprise Defense Systems

WIIM

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Amylyx Pharmaceuticals shares are trading higher after the FDA has lifted the clinical hold on its Phase 1 trial of AMX0114 for the treatment of amyotrophic lateral sclerosis.

Amylyx Pharmaceuticals Announces FDA Lifts Clinical Hold On AMX0114 Phase 1 Clinical Trial In Treatment Of Amyotrophic Lateral Sclerosis

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Valvoline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVV#NYSE">VVV</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Valvoline, presenting an average target of $43.25, a high estimate of $46.00, and a low estimate of $38.00. A 8.25% drop is evident in the current average compared to the previous average price target of $47.14. 
<img src="https://www.benzinga.com/files/images/story/2025/1737468072_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Valvoline. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>David Bellinger</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$42.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Chris O'Cull</td>
<td>Stifel</td>
<td>Announces</td>
<td>Hold</td>
<td>$42.00</td>
<td>-</td>
</tr>
<tr>
<td>David Bellinger</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$46.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Steven Shemesh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$46.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>David Lantz</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Justin Kleber</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$46.00</td>
<td>$48.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Valvoline. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Valvoline compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Valvoline's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VVV/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Valvoline analyst ratings.</a>
<h2>About Valvoline</h2>
Valvoline Inc produces, markets, and sells automotive maintenance products, particularly lubricants, to retail outlets installers, and customers. The company offers various products such as engine oil, heavy-duty engine oil, motorcycle oil, grease and brake fluid, and others. Geographically, the majority of the revenue is generated from the United States of America.
<h3>Financial Milestones: Valvoline's Journey</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Valvoline's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.67% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Valvoline's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 21.19% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Valvoline's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 63.2%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Valvoline's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.83% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 7.4, caution is advised due to increased financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Valvoline: Insights From 8 Financial Analysts

American States Water Announced CPUC's Final Decision On BVES's Rate Case, Setting New Electric Rates For 2023-2026, Effective March 2025; Retroactive Rate Recovery And Wildfire Costs Included; Financial Terms Not Disclosed

4 analysts have shared their evaluations of AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for AudioEye, revealing an average target of $30.5, a high estimate of $37.00, and a low estimate of $25.00. Marking an increase of 17.31%, the current average surpasses the previous average price target of $26.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1737468059_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of AudioEye's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$25.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Buck</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$37.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Richard Baldry</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AudioEye. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of AudioEye compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of AudioEye's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of AudioEye's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AEYE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AudioEye analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering AudioEye: A Closer Look</h2>
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's, and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.
<h3>Financial Milestones: AudioEye's Journey</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, AudioEye showcased positive performance, achieving a revenue growth rate of 13.87% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: AudioEye's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -13.47%, the company may face hurdles in effective cost management.
Return on Equity (ROE): AudioEye's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -19.69%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -4.68%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: AudioEye's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.31, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEYE

Forecasting The Future: 4 Analyst Projections For AudioEye

5 analysts have shared their evaluations of Navient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAVI#NASDAQ">NAVI</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $15.1, a high estimate of $18.00, and a low estimate of $13.00. Highlighting a 1.82% decrease, the current average has fallen from the previous average price target of $15.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1737468045_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Navient among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bill Ryan</td>
<td>Seaport Global</td>
<td>Announces</td>
<td>Buy</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$13.50</td>
<td>$15.00</td>
</tr>
<tr>
<td>Nathaniel Richam-Odoi</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$15.50</td>
</tr>
<tr>
<td>Moshe Orenbuch</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Sell</td>
<td>$13.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Navient. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Navient compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Navient's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Navient's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NAVI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Navient analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Navient</h2>
Navient Corp provides technology-enabled education finance and business processing solutions that simplify complex programs and help millions of people achieve success. It operates business in three segments: Federal Education Loans, Consumer Lending and Business Processing.
<h3>Navient: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: Navient's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -58.06%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Navient's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -1.13%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Navient's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.07%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Navient's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.0%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 18.32, Navient faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NAVI

Analyst Expectations For Navient's Future

Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look

BIO, the global lobbying organization for biotechnology firms, forced WuXi AppTec to leave the group due to pressure from the US Congress. Also, Boehringer Ingelheim acquired an option to license drug candidates that treat symptoms of schizophrenia.

Week In Review: Under Pressure From US Congress, WuXi AppTec Resigns From BIO

Week In Review: Under Pressure From U.S. Congress, WuXi AppTec Resigns From BIO

Amgen posts late-stage win for Uplizna in immune-mediated disorder

Silence Therapeutics achieves $2M research milestone payment from Hansoh Pharma

Merck enters obesity drug race in pact with Chinese pharma Hansoh

Merck-Hansoh deal for oral GLP-1 hurts obesity drug developers

Chinese biotech dominance in R&D is on the rise

ABBV

AKESF

AMGN

ASLN

AZNCF

GPCR

MTVA

NVSEF

REGMF

RHHBF

RHHBY

SLNCF

SMMT

SOLTF

TERN

VKTX

WUXAY

WUXIF

Hansoh Pharmaceutical Gr

Comments

Hansoh Pharmaceutical Gr

Hansoh Pharmaceutical Gr (HNSPF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga